Back to Results
First PageMeta Content
Lung cancer / Organofluorides / Organochlorides / Pfizer / Quinazolines / Crizotinib / Non-small-cell lung carcinoma / Anaplastic lymphoma kinase / ALK inhibitor / Medicine / Chemistry / Oncology


Microsoft Word[removed]ALK-Final DAP.docx
Add to Reading List

Document Date: 2015-03-20 01:49:46

Open Document

File Size: 585,89 KB

Share Result on Facebook

Company

McDermott / Vysis ALK Break Apart FISH Probe Kit / Pfizer Australia Pty Ltd / Abbott Molecular Diagnostics / Abbott Australasia Pty Ltd / /

Country

Australia / /

Currency

pence / USD / /

Event

FDA Phase / /

Facility

Australian Institute of Health / Royal College of Pathologists / /

IndustryTerm

transportation / clinical algorithms / pharmaceutical agent crizotinib / healthcare resources / in-vitro diagnostic medical device / decision analytic protocol / /

MedicalCondition

Squamous cell carcinoma / cancer / disease / NSCLC / surgically resected tumours / advanced lung cancer / adenocarcinoma histology / tumour / squamous carcinomas / metastatic disease / lung cancer / nonsmall cell lung cancer / additional lung cancer / advanced non-small cell lung cancer / anaplastic lymphoma kinase / earlier stage disease / lung cancers / /

MedicalTreatment

combination chemotherapy / /

Organization

Royal College of Pathologists of Australasia / Australian Institute of Health and Welfare / Department of Health / Medical Services Advisory Committee / National Association of Testing Authorities / medicare / /

Person

Solomon / Francis / Ageing / /

Position

Minister / respiratory physician / pathologist / treating physician / /

Product

ALK / /

Technology

decision analytic protocol / Clinical algorithms / antibodies / hybridization / chemotherapy / 1250 Final Decision Analytic Protocol / undertaken using combination chemotherapy / /

SocialTag